Indaptus Therapeutics, Inc. (INDP) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 New York City, NY, 美国. 现任CEO为 David Elliot Lazar.
INDP 拥有 IPO日期为 2015-08-04, 7 名全职员工, 在 NASDAQ Capital Marke, 市值为 $4.08M.
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
